VolitionRx Limited (NYSE American: VNRX) announced the filing of a strategic patent application covering the use of its proprietary Nu.Q technology for triaging and monitoring patients suspected of having contracted the Ebola virus. The application builds on the company's existing Nu.Q® NETs test, which measures circulating nucleosomes and neutrophil extracellular traps as early indicators of hyper-inflammation associated with septic shock and mortality.
Volition said its CE-Marked automated Nu.Q NETs assay and recently developed finger-prick lateral flow detection prototype could provide a low-cost bedside triage solution during Ebola outbreaks, particularly in resource-constrained regions. The company is seeking partnerships with global health organizations, pharmaceutical developers, NGOs and distribution partners to support field trials, manufacturing scale-up and potential deployment in outbreak zones.
The patent application represents a significant step in expanding Volition's intellectual property portfolio beyond its core focus on cancer and sepsis diagnostics. By applying its Nu.Q technology to Ebola, the company addresses a critical need for rapid, affordable triage tools in regions where outbreaks often overwhelm healthcare systems. The lateral flow prototype, similar to a pregnancy test, could enable frontline workers to quickly identify patients requiring isolation and intensive care, potentially reducing transmission and mortality.
Volition's Nu.Q NETs test detects neutrophil extracellular traps, which are released during NETosis—a process linked to severe inflammation in conditions like sepsis and now Ebola. The company's existing CE-Mark for the automated assay provides a regulatory pathway, while the lateral flow device aims to bring testing to point-of-care settings without laboratory infrastructure. Partnerships with global health bodies like the World Health Organization or Médecins Sans Frontières could accelerate validation and deployment.
This expansion into infectious disease triage highlights the versatility of Volition's epigenetic platform. The company continues to develop blood tests for early detection and monitoring of diseases, with potential to improve outcomes in both human and animal health. The full press release is available at https://ibn.fm/UOWP1.
For further information about Volition and its technology, visit the company's website at https://volition.com/.
